| Q37333126 | A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy |
| Q85007169 | Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ |
| Q33403655 | Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay |
| Q45731159 | Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. |
| Q85035495 | Adjuvant zoledronic acid for breast cancer: mechanism of action? |
| Q37418209 | Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis |
| Q99571885 | Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study |
| Q33905819 | Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. |
| Q39158802 | Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas. |
| Q36759195 | Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate |
| Q36194639 | Anti-lymphoma effect of gammadelta T cells |
| Q37794160 | Anticancer Properties of Zoledronic Acid |
| Q37845836 | Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. |
| Q37812731 | Antitumor Effects and Anticancer Applications of Bisphosphonates |
| Q40070853 | BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain |
| Q55515922 | Bisphosphonate conjugation for bone specific drug targeting. |
| Q37307297 | Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis |
| Q41829362 | Bisphosphonates and cancer: what opportunities from nanotechnology? |
| Q92604203 | Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women |
| Q36963360 | Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate! |
| Q38283536 | Cancer Immunotherapy Using γδT Cells: Dealing with Diversity |
| Q64101475 | Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer |
| Q37127038 | Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. |
| Q44952617 | Contribution of complementarity-determining region 3 of the T-cell receptor Vdelta2 chain to the recognition of aminobisphosphonates by human gammadelta T-cells |
| Q53962822 | Could γ/δ T Cells Explain Adverse Effects of Zoledronic Acid? Comment on the Article by Reinhardt et al. |
| Q47100174 | Current Advances in γδ T Cell-Based Tumor Immunotherapy |
| Q35212837 | Current immunotherapeutic approaches in pancreatic cancer. |
| Q90259222 | Development and Selection of the Human Vγ9Vδ2+ T-Cell Repertoire |
| Q41919355 | Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy |
| Q50550722 | Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer. |
| Q38955517 | Drugs in early clinical development for the treatment of osteosarcoma |
| Q96303605 | Emerging Challenges of Preclinical Models of Anti-tumor Immunotherapeutic Strategies Utilizing Vγ9Vδ2 T Cells |
| Q39585660 | Expansion of human peripheral blood γδ T cells using zoledronate |
| Q47601332 | Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? |
| Q46751057 | Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction |
| Q36424129 | Gamma/Delta T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. |
| Q37245433 | Gammadelta T lymphocyte homeostasis is negatively regulated by beta2-microglobulin |
| Q37207554 | Gammadelta T-cells: potential regulators of the post-burn inflammatory response |
| Q34018807 | HMGB1 and cord blood: its role as immuno-adjuvant factor in innate immunity |
| Q34009853 | How do bisphosphonates inhibit bone metastasis in vivo? |
| Q42740131 | How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases. |
| Q36908780 | Human gamma delta T cells: candidates for the development of immunotherapeutic strategies |
| Q45002846 | Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity |
| Q38040743 | IL-17-producing γδ T cells and innate lymphoid cells |
| Q37955974 | Immune regulation of the tumor/bone vicious cycle |
| Q36871994 | Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity |
| Q45964358 | Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. |
| Q55311835 | Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. |
| Q43057295 | In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients |
| Q35889808 | Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism |
| Q39588867 | Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer |
| Q38177689 | Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases |
| Q36938527 | Interference with immune-cell-mediated bone resorption in periodontal disease |
| Q58903536 | Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells |
| Q34395222 | Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells |
| Q36498963 | Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates |
| Q50932570 | Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. |
| Q38299932 | Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities |
| Q38818271 | Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. |
| Q64229240 | Optimized protocols for γδ T cell expansion and lentiviral transduction |
| Q36334874 | Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma |
| Q37226209 | Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma. |
| Q38172562 | Phenotypic and functional plasticity of gamma-delta (γδ) T cells in inflammation and tolerance |
| Q35226178 | Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma |
| Q37359744 | Polysaccharides derived from Yamoa (Funtumia elastica) prime gammadelta T cells in vitro and enhance innate immune responses in vivo |
| Q28742327 | Polysaccharides isolated from Açaí fruit induce innate immune responses |
| Q38265506 | Potential Use of γδ T Cell-Based Vaccines in Cancer Immunotherapy. |
| Q35896206 | Potential of human gammadelta T lymphocytes for immunotherapy of cancer |
| Q35667318 | Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives |
| Q34802235 | Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro |
| Q47678544 | Reconstitution of T and NK cells after haploidentical hematopoietic cell transplantation using αβ T cell-depleted grafts and the clinical implication of γδ T cells. |
| Q37731978 | Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells |
| Q37362470 | Response of gammadelta T Cells to plant-derived tannins. |
| Q38051222 | Role of gamma-delta T-cells in cancer: another opening door to immunotherapy |
| Q37018333 | Significance and impact of bisphosphonate-induced acute phase responses |
| Q34612619 | T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody |
| Q28659468 | Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer |
| Q39255203 | The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture |
| Q36491653 | The anti-tumour effects of zoledronic acid |
| Q34309388 | The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors |
| Q37172099 | The invisible arm of immunity in common cancer chemoprevention agents |
| Q46832072 | The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. |
| Q35677421 | Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells |
| Q38287973 | Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment. |
| Q59535965 | Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates |
| Q37876363 | Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. |
| Q38811197 | Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma |
| Q34230320 | Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates |
| Q26849323 | What lessons can be learned from γδ T cell-based cancer immunotherapy trials? |
| Q40252845 | Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity. |
| Q38875042 | Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. |
| Q33739204 | Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? |
| Q28744548 | Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model |
| Q37294327 | Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. |
| Q39424272 | Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug |
| Q45953271 | Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells. |
| Q36803818 | Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells |
| Q36732665 | gammadelta T cells: novel initiators of adaptive immunity. |
| Q34055649 | {gamma}{delta} T cell homeostasis is established in competition with {alpha}{beta} T cells and NK cells |
| Q26995102 | γδ T Cell Immunotherapy-A Review |
| Q52649705 | γδ T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors. |
| Q57425152 | γδ T cells: an immunotherapeutic approach for HIV cure strategies |
| Q37875768 | γδ T-APCs: a novel tool for immunotherapy? |
| Q26994963 | γδ-T cells: an unpolished sword in human anti-infection immunity |
| Q38271585 | γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy |